Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy

Barbour, A.P. (A. P.), Brosda, S. (S.), B.P.L. Wijnhoven (Bas), van Hootgem, S. (S.), Lanschot, J.J.B. (J. J.B.), Barbour, S. (S.), S.M. Lagarde (Sjoerd), Krause, L. (L.), Pryor, D. (D.), Thomas, J. (J.), et al. Smithers, M. (M.)

2018-10-01

Annals of Oncology , Volume 29 p. viii212

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdy282.015, hdl.handle.net/1765/125546
Journal	Annals of Oncology
Organisation	Department of Surgery
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Barbour, A.P. (A. P.), Brosda, S. (S.), Wijnhoven, B., van Hootgem, S. (S.), Lanschot, J.J.B. (J. J.B.), Barbour, S. (S.), … Smithers, M. (M.). (2018). Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy. Annals of Oncology, 29. doi:10.1093/annonc/mdy282.015

Publication